COVID-19 Therapeutics: Modality, Efficacy and Implications for Access

12:00 PM - 12:45 PM (EDT), Monday, June 14, 2021
Search General Info
Search Education
Search Partnering Companies
As COVID-19 infections spread around the world, companies moved swiftly to test many of the products in their pipelines. This has led to a broad array of novel approaches to treating patients infected with the virus—from antibodies that could be given as prevention, to treatments that help reduce the impact of the “cytokine storm,” or Acute Respiratory Distress Syndrome (ARDS). Hear from top scientists and industry leaders about the development of these non-vaccine treatment options and the challenges in achieving global access to them.
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovation Organization